Metabolic dysfunction-associated fatty liver disease: an update.

IF 4.2 Q2 PHARMACOLOGY & PHARMACY

Australian Prescriber Pub Date : 2026-04-01 DOI:10.18773/austprescr.2026.014

Richard O'Halloran, Leon A Adams, Gary Deed, John S Lubel

引用次数: 0

Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) affects 1 in 3 Australian adults and is an under-recognised but growing cause of liver cirrhosis, hepatocellular carcinoma and liver transplantation. There is a major role for primary care in MAFLD prevention, diagnosis and management. Adults with obesity, type 2 diabetes or other metabolic risk factors should be assessed for MAFLD. Liver ultrasound is the recommended first-line test for diagnosing hepatic steatosis (fat accumulation in hepatocytes). Management of MAFLD includes noninvasive testing for liver fibrosis, addressing health risk behaviours and comorbidities, and hepatocellular carcinoma surveillance in those with liver cirrhosis.

查看原文本刊更多论文

代谢功能障碍相关的脂肪肝疾病：最新进展

代谢功能障碍相关的脂肪性肝病（MAFLD）影响了三分之一的澳大利亚成年人，是肝硬化、肝细胞癌和肝移植的一个未被充分认识但日益增长的病因。初级保健在马蹄疫的预防、诊断和管理方面发挥着重要作用。患有肥胖、2型糖尿病或其他代谢危险因素的成年人应进行MAFLD评估。肝脏超声是诊断肝脂肪变性（肝细胞脂肪堆积）的首选检查。MAFLD的管理包括肝纤维化的无创检测，解决健康风险行为和合并症，以及肝硬化患者的肝细胞癌监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY

CiteScore

3.80

自引率

7.40%

发文量

审稿时长

>12 weeks

期刊介绍： Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.